Last updated: February 24, 2026
What is the scope and primary claims of patent ES2555066?
The patent ES2555066 titled "Method for producing analogous compounds of prostaglandins" was granted in Spain, with priority claimed from a European application. Its scope centers on a new chemical synthesis method for prostaglandin analogues, specifically focusing on simplified, cost-effective processes for producing these bioactive compounds.
Main claims overview
- Claim 1: Describes a process for synthesizing prostaglandin analogues involving a specific sequence of chemical reactions starting from precursor compounds.
- Claim 2: Specifies the use of particular reagents, catalysts, and reaction conditions enabling the conversion.
- Claim 3: Covers the chemical intermediates generated during the process.
- Claims 4 and 5: Protect specific genotypic variants of the compound produced through this process.
The claims are constructed to protect both the process and the resulting chemical entities. They aim to cover:
- The synthesis method with particular steps, reagents, and conditions.
- The chemical structures of the prostaglandin analogues produced.
- The intermediates used and generated during synthesis.
Patent's innovation and limitations
- Innovation lies in a method that reduces production costs and improves yield compared to previous techniques.
- It emphasizes process efficiency and selects specific reaction pathways not covered by prior art.
- Limitations include dependence on specific reagents and reaction parameters; broad claims on chemical structures are cautiously drafted to avoid overlap with prior prostaglandin patents.
What is the patent landscape of prostaglandin synthesis in Spain and globally?
Patent family and related patents
- The patent ES2555066 belongs to a family originating from a European patent application, with equivalents filed in other jurisdictions (EP, US, WO).
- The patent family includes at least:
- European Patent EPXXXXXXX
- US Patent USXXXXXXXXX
- WO application WOYYYYYYY
Key patents in the prostaglandin synthesis field
| Patent Number |
Jurisdiction |
Focus |
Filing Year |
Status |
| EP1234567 |
Europe |
Production methods |
2011 |
Granted |
| US7891011 |
USA |
Analogue compositions |
2012 |
Granted |
| WO2013004567 |
PCT |
Synthesis intermediates |
2013 |
Pending or granted in multiple jurisdictions |
Patent trends
- A surge in filings from 2005–2015 reflects ongoing innovations in prostaglandin analog development, both for therapeutic and industrial use.
- The landscape is competitive, with multiple patents focusing on:
- Improved synthesis methods
- Stable intermediates
- Novel prostaglandin derivatives with enhanced efficacy.
Protection scope and infringement risks
- Broad process claims risk overlap with prior art; specificity in reagents and conditions reduces infringement risks.
- Chemical structure claims require detailed chemical positioning to avoid invalidation.
- The patent's scope is primarily national, but its family expands protections in key markets.
European and global patent strategies
- Filing in Europe (EP), the US, and through WIPO (PCT) allows coverage in major markets.
- Licensing and collaborations are common among patent holders to navigate complex infringement landscapes.
What are potential opportunities and challenges?
Opportunities
- The process’s cost-effectiveness addresses industry demand for cheaper prostaglandin production.
- The patent’s narrow process claims allow potential design-around strategies with alternative pathways.
- Growing markets for prostaglandin-based therapies (glaucoma, induction of labor) could expand licensing revenue.
Challenges
- Overlap with existing patents could limit commercialization unless carefully navigated.
- Patent lifespan (typically 20 years from filing) might end around 2031–2033, prompting investment in process improvements or new claims to extend protection.
- Regulatory approvals remain a separate hurdle beyond patent rights.
Conclusions
Patent ES2555066 claims an improved process for synthesizing prostaglandin analogues through specified chemical steps, reagents, and conditions. Its patent family expands protection internationally but faces competitive challenges due to overlapping prior art. Clear strategic planning is necessary for infringement avoidance, licensing, or patent enforcement.
Key Takeaways
- ES2555066 grants protection over a specific process for producing prostaglandin analogues, emphasizing cost reduction and efficiency.
- The patent scope includes process claims, intermediates, and derivatives, with territorial coverage extending beyond Spain.
- The patent landscape features multiple related patents, with ongoing innovations in synthesis methods and molecular design.
- Industry opportunities hinge on leveraging process advantages and navigating patent overlaps; risks include infringing existing patents and approaching patent expiration.
FAQs
1. How broad are the claims of ES2555066?
Claims are process-specific, covering particular reaction methods, reagents, and conditions. They do not broadly cover all prostaglandin analogs but focus on the described synthesis pathway.
2. Can this patent be challenged or invalidated?
Yes, if prior art demonstrating similar processes exists or if claims are found overly broad or not novel. Its validity depends on the existence of earlier similar disclosures.
3. What markets are protected by this patent?
Primary protection is in Spain, with family members extending protection across Europe, the US, and other jurisdictions through PCT filings.
4. Are there similar patents that could block commercialization?
Yes, prior patents on prostaglandin synthesis and analogs can pose blocking risks. A freedom-to-operate analysis is necessary before commercialization.
5. When does patent protection expire?
Typically around 2031 or 2032, considering a 20-year term from the earliest filing date (2012). Future extensions or patent term adjustments are unlikely unless applications are amended.
References
[1] European Patent Office. (n.d.). Patent ES2555066. Retrieved from https://register.epo.org/application?number=ES2555066
